Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma.

abstract：:The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies wile the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare....

journal_title：Leukemia & lymphoma

authors： Montefusco E,Fazi F,Cordone I,Ariola C,Nanni M,Spadea A,Spiriti MA,Fenu S,Mandelli F,Petti MC

更新日期：2001-02-01 00:00:00

abstract：:Clonal bone marrow (BM) B-cell populations are a common finding in patients with suspected primary central nervous system lymphoma (PCNSL). To assess their clinical significance, benign monoclonal B-cell lymphocytosis (MBL) needs to be differentiated from concomitant BM involvement, since patients with secondary centr...

journal_title：Leukemia & lymphoma

authors： Brandt A,Matschke J,Fehrle W,von Wenserski L,Bokemeyer C,Illerhaus G,Binder M

更新日期：2019-02-01 00:00:00

abstract：:Beclin-1 is a key regulator of autophagy and has been suggested to be involved in the development of drug resistance in multiple myeloma (MM). We analyzed the expression of Beclin-1 in a retrospective cohort of 70 MMs. Beclin-1 expression did not influence overall survival (OS) and progression-free survival (PFS) in p...

journal_title：Leukemia & lymphoma

authors： Willenbacher W,Thangavadivel S,Greil R,Willenbacher E,Weger R,Manzl C,Jöhrer K,Brunner A

更新日期：2016-10-01 00:00:00

abstract：:Information on the use of hypomethylating agents (HMAs) as a pre-transplant cytoreductive therapy in MDS is limited. We retrospectively evaluated outcomes of 172 adult MDS patients, who underwent allogeneic hematopoietic stem cell transplantation between January 2000 and December 2016. Patients were divided into three...

journal_title：Leukemia & lymphoma

authors： Modi D,Kim S,Singh V,Ayash L,Alavi A,Ratanatharathorn V,Uberti JP,Deol A

更新日期：2019-11-01 00:00:00

abstract：:The in vitro proliferative response of purified B-chronic lymphocytic leukemia (B-CLL) lymphocytes cultured in the presence of soluble CD23 (sCD23) with or without IL2 was compared to the responses induced by phorbol 12-myristate 13-acetate (PMA), Staphylococcus aureus strain Cowan I (SAC), IL1, IL2, IL4, IL6 and the ...

journal_title：Leukemia & lymphoma

authors： Brizard A,Morel F,Lecron JC,Dreyfus B,Brizard F,Barra A,Preud'homme JL

更新日期：1994-07-01 00:00:00

abstract：:Renal involvement in patients with lymphoma is rare but associated with poor prognosis. We analyzed characteristics and outcome of 22 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and renal involvement treated with a rituximab-containing regimen in curative intent. The majority of patients presen...

journal_title：Leukemia & lymphoma

authors： Lehners N,Krämer I,Schwarzbich MA,Ho AD,Witzens-Harig M

更新日期：2016-11-01 00:00:00

abstract：:Patients with hematological malignancies who relapse after bone marrow transplantation (BMT) are often treated with donor lymphocyte infusion. However, this procedure often results in graft-versus-host disease (GVHD). While, Dendritic cells (DCs), which present antigens to naive T cells, have been used in the immunoth...

journal_title：Leukemia & lymphoma

authors： Fujii S,Shimizu K,Fujimoto K,Kiyokawa T,Tsukamoto A,Sanada I,Kawano F

更新日期：2001-07-01 00:00:00

abstract：:Normal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal...

journal_title：Leukemia & lymphoma

authors： Geldart T,Illidge T

更新日期：2005-08-01 00:00:00

abstract：:Little is known about disparities in myelodysplastic syndromes (MDS). We performed a retrospective chart review of patients with MDS (n = 252) evaluated at the University of Maryland Greenebaum Cancer Center between 2000 and 2010. The median age at diagnosis was 65 years, which was lower than the median age of 76 year...

journal_title：Leukemia & lymphoma

authors： Zandberg DP,Hendrick F,Vannorsdall E,Bierenbaum J,Tidwell ML,Ning Y,Zhao XF,Davidoff AJ,Baer MR

更新日期：2013-02-01 00:00:00

abstract：:The outcome of sixty-four patients with acute leukemia in first remission who had been treated with either bone marrow transplantation (BMT) or conventional chemotherapy was retrospectively evaluated (a median follow-up of 37 months). Among them, 26 patients (age range; 14-42 years) received allogeneic BMT from HLA-id...

journal_title：Leukemia & lymphoma

authors： Tamura S,Takemoto Y,Kanamaru A,Fujiwara H,Miyazaki E,Fujimori Y,Inoue N,Okamoto T,Kohsaki M,Kakishita E

更新日期：1992-11-01 00:00:00

abstract：:Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymph...

journal_title：Leukemia & lymphoma

authors： Ianotto JC,Ngo Sack F,Couturier MA,Tempescul A,Mugnier N,Delepine P,Guillerm G,Berthou C

更新日期：2014-01-01 00:00:00

abstract：:Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

journal_title：Leukemia & lymphoma

authors： Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

更新日期：2007-01-01 00:00:00

abstract：:Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

journal_title：Leukemia & lymphoma

authors： Cummins KD,Gill S

更新日期：2018-07-01 00:00:00

abstract：:Even though amphotericin B is associated with considerable hematological toxicity, this subject has been poorly studied. This retrospective cohort study assessed the incidence and predictors of hematological toxicity in patients treated with different amphotericin B formulations: amphotericin B deoxycholate (d-AmB), l...

journal_title：Leukemia & lymphoma

authors： Falci DR,da Rosa FB,Pasqualotto AC

更新日期：2015-01-01 00:00:00

abstract：:While more than 75% of the adult patients with acute lymphoblastic leukemia (ALL) achieve a complete remission after treatment with intensive chemotherapy, about 40% of them relapse within five years. These relapses are probably due to residual leukemic cells. Gene rearrangements are used as markers of clonality and t...

journal_title：Leukemia & lymphoma

authors： Knauf WU,Ho AD,Heger G,Hoelzer D,Hunstein W,Thiel E

更新日期：1991-01-01 00:00:00

abstract：:We review results of intensive chemotherapy (IC) obtained in myelodysplastic syndromes (MDS). Overall, the complete remission (CR) rates and median CR duration obtained with IC are low in MDS, especially when compared to results obtained in de novo AML treated with the same chemotherapy regimens; very few MDS patients...

journal_title：Leukemia & lymphoma

authors： Fenaux P,Preudhomme C,Hebbar M

更新日期：1992-09-01 00:00:00

abstract：:We performed double autologous PBSCT in one fulminantly relapsed ATL patient. Cryopreserved PBSCs containing tumour cells were thawed, and CD34+ cells were selected for by immunomagnetic beads, with the aim of decreasing the number of re-infused tumour cells. The patient received 0.72x10(6) and 0.90x10(6) CD34+ cells/...

journal_title：Leukemia & lymphoma

authors： Watanabe J,Kondo H,Hatake K

更新日期：2001-09-01 00:00:00

abstract：:Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest...

journal_title：Leukemia & lymphoma

authors： Hawley RG,Berger LC

更新日期：1998-05-01 00:00:00

abstract：:Sensitivity to doxorubicin (DOX) and expression of intracellular endogenous TNF (enTNF) or manganous superoxide dismutase (MnSOD) activity were found to be inversely correlated in leukemic cells from 19 patients (6 acute lymphoblastic leukemia, 13 acute myeloblastic leukemia). In a case with acquired resistance to che...

journal_title：Leukemia & lymphoma

authors： Watanabe N

更新日期：1998-08-01 00:00:00

abstract：:Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patie...

journal_title：Leukemia & lymphoma

authors： Mazzotta S,Gozzetti A,Pirrotta MT,Bocchia M,Sammassimo S,Bucalossi A,Lauria F

更新日期：2005-12-01 00:00:00

abstract：:Two patients presented with anasarca, fevers and sweats. Subsequent evaluation revealed aggressive lymphoproliferative disease. Both patients were treated with CHOP chemotherapy. One patient responded with spontaneous, vigorous diuresis and complete resolution of the edema. She relapsed two months later with recurrent...

journal_title：Leukemia & lymphoma

authors： Jillella AP,Day DS,Severson K,Kallab AM,Burgess R

更新日期：2000-07-01 00:00:00

abstract：:We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 month...

journal_title：Leukemia & lymphoma

authors： Chong EA,Svoboda J,Cherian S,Andreadis C,Downs LH,Zhuang H,Alavi A,Tsai DE,Schuster SJ

更新日期：2005-09-01 00:00:00

abstract：:Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell p...

journal_title：Leukemia & lymphoma

authors： Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

更新日期：2002-05-01 00:00:00

abstract：:Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. Effective control of disease may also set the stage for eventual 'cure' of this leukemia. However, the existence of Philade...

journal_title：Leukemia & lymphoma

authors： Donato NJ,Peterson LF

更新日期：2011-02-01 00:00:00

abstract：:Myeloperoxidase (MPO) has been shown to catalyze the in vitro degradation of vincristine (VCR). Given that MPO is a lysosomal enzyme that can be released into the circulation by both normal activated and leukemic myeloid cells, we investigated the possibility that sera from patients with acute myeloblastic leukemia (A...

journal_title：Leukemia & lymphoma

authors： Schlaifer D,Duchayne E,Demur C,Alvinerie P,Muller C,Attal M,Cooper MR,Payen C,Monsarrat B,Myers CE,Pris J,Laurent G

更新日期：1996-02-01 00:00:00

abstract：:Monoclonal proteins (paraproteins) may be detected in the sera in approximately 1% of the general population and are frequently associated with peripheral neuropathy. Paraproteinemic neuropathy (PPN) is most commonly associated with monoclonal gammopathy of undetermined significance, and may also occur in the context ...

journal_title：Leukemia & lymphoma

authors： Zivković SA,Lacomis D,Lentzsch S

更新日期：2009-09-01 00:00:00

abstract：:Hodgkin lymphomas are characterised by the presence of rare malignant cells in a background of non-neoplastic inflammatory cells. Flow cytometric analysis of involved tissues is generally not thought to be useful in establishing the diagnosis, because of the small number of neoplastic cells present. However, two recen...

journal_title：Leukemia & lymphoma

authors： Rahemtullah A,Harris NL,Dorn ME,Preffer FI,Hasserjian RP

更新日期：2008-10-01 00:00:00

abstract：:The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...

journal_title：Leukemia & lymphoma

authors： Arrowsmith ER,Macon WR,Kinney MC,Stein RS,Goodman SA,Morgan DS,Flexner JM,Cousar JB,Jagasia MH,McCurley TL,Greer JP

更新日期：2003-02-01 00:00:00

abstract：:Aberrant expression of the B lymphoid marker, CD19, in acute myeloid leukemia (AML) has frequently been associated with t(8;21)(q22;q22). However, AML cases lacking t(8;21) may occasionally express CD19. We asked whether CD19 expression is restricted to the karyotypically abnormal leukemic cells in primary leukemia sa...

journal_title：Leukemia & lymphoma

authors： Francis J,Dharmadhikari AV,Sait SN,Deeb G,Wallace PK,Thompson JE,Wang ES,Wetzler M

更新日期：2013-07-01 00:00:00

abstract：:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary...

journal_title：Leukemia & lymphoma

authors： Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

更新日期：2000-02-01 00:00:00